Beam Therapeutics Unternehmenswert
Was ist das Unternehmenswert von Beam Therapeutics?
Unternehmenswert von Beam Therapeutics Inc. ist $2.24B
Was ist die Definition von Unternehmenswert?
Der Unternehmenswert ist ein Maß für den gesamten Marktwert eines Unternehmens. Es wird als Marktkapitalisierung mit Verschuldung, Minderheitsanteilen und Vorzugsaktien abzüglich der Zahlungsmittel und Zahlungsmitteläquivalente berechnet.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Unternehmenswert von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Beam Therapeutics
Was macht Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Unternehmen mit unternehmenswert ähnlich Beam Therapeutics
- Stepan Co hat Unternehmenswert von $2.23B
- Biffa Plc hat Unternehmenswert von $2.24B
- Minmetals Land hat Unternehmenswert von $2.24B
- Morneau Shepell hat Unternehmenswert von $2.24B
- Kajaria Ceramics hat Unternehmenswert von $2.24B
- Polar Capital Technology Trust Plc hat Unternehmenswert von $2.24B
- Beam Therapeutics hat Unternehmenswert von $2.24B
- InnoCare Pharma hat Unternehmenswert von $2.24B
- Global Blue AG hat Unternehmenswert von $2.24B
- Consolidated Communications Inc hat Unternehmenswert von $2.24B
- Brookfield Asset Management Re hat Unternehmenswert von $2.24B
- Indivior PLC hat Unternehmenswert von $2.25B
- Rail Vikas Nigam hat Unternehmenswert von $2.25B